Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,535.00    11.00 (0.72%)
Bid:
1,534.00
Ask:
1,536.00
Spread: 2.00 (0.13%)
Market Cap: £3.23b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

LTIP Awards

30 Apr 2008 15:22

Hikma Pharmaceuticals Plc30 April 2008 Hikma Pharmaceuticals PLC - LTIP Awards LONDON, 30 April 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)announces that the Remuneration Committee has made the following nil-cost awardsunder the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the "LTIP")to Directors and Persons Discharging Managerial Responsibility ("PDMRs") of theCompany. Awards under the LTIP were made on 29 April 2008 at a price of £4.64 perordinary share as follows:- Name of Director/PDMR Number of LTIP SharesSaid Darwazah 90,000Mazen Darwazah 54,000Bassam Kanaan 54,000Taghreed Al-Shunnar 54,000Majda Labadi 54,000Nabil Rizk 54,000 The shares subject to the LTIP awards will only be released to the participantsin three years time, subject to their continued employment and the satisfactionof the comparative Total Shareholder Return ("TSR") performance target.Participants will only receive the full benefit of their share incentives if TSRperformance against the Comparator Group is at least at the upper quartile. - ENDS -Enquiries: Hikma Pharmaceuticals PLCHenry Knowles +44 20 7399 2760Company Secretary Susan Ringdal +44 20 7399 2760Investor Relations Director About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and"Generics". Hikma's operations are based principally in the Middle East andNorth Africa ("MENA") region, where it is a market leader and sells across 17countries, the United States and Europe. In 2007, the Group achieved revenuesof $449 million (2006 $317 million) and profit attributable to shareholders was$63 million (2006 $55 million). For news and other information, please visitwww.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
31st Mar 20082:43 pmRNSDirector/PDMR Shareholding
18th Mar 20087:02 amRNSPreliminary Results
4th Mar 20083:25 pmRNSVoting Rights and Capital
7th Feb 20087:00 amRNSVoting Rights and Capital
21st Jan 20082:58 pmRNSNotification of transaction
17th Jan 20082:02 pmRNSResult of Equity Issue
17th Jan 20087:01 amRNSTrading Update
17th Jan 20087:01 amRNSIssue of Equity
8th Jan 20083:46 pmRNSDirector/PDMR Shareholding
7th Jan 20081:17 pmRNSDirector/PDMR Shareholding
2nd Jan 200812:48 pmRNSDirector/PDMR Shareholding
2nd Jan 20089:49 amRNSDirector/PDMR Shareholding
17th Dec 20072:05 pmRNSDirector/PDMR Shareholding
14th Dec 20077:01 amRNSPre-close trading statement
10th Dec 20071:19 pmRNSHikma acquires APM
30th Nov 200711:18 amRNSVoting Rights and Capital
21st Nov 20073:56 pmRNSUpdate on Lisinopril Contract
31st Oct 20074:51 pmRNSLegal and General DTR Announc
15th Oct 20075:06 pmRNSDirector / PDMR Shareholding
8th Oct 20077:01 amRNSConditional cash offer
8th Oct 20077:00 amRNSBlock Listing of Shares
5th Oct 20077:00 amRNSBlocklisting - 6 Month Review
19th Sep 20074:22 pmRNSOption Exercise
14th Sep 20072:58 pmRNSDirector/PDMR Shareholding
11th Sep 20074:28 pmRNSNotification of transaction
7th Sep 20072:20 pmRNSNotification of transaction
5th Sep 20077:02 amRNSInterim Results 2007
9th Aug 20077:00 amRNSHikma enters Egyptian market
27th Jun 20077:01 amRNSPre-close trading statement
6th Jun 20071:45 pmRNSAGM Statement
6th Jun 20077:00 amRNSAGM Statement
14th May 20074:42 pmRNSAnnual information update
23rd Apr 20071:33 pmRNSHikma appoints new CEO
20th Apr 20072:57 pmRNSHikma acquires Thymoorgan
5th Apr 20079:50 amRNSBlock Listing 6-month review
5th Apr 20079:35 amRNSNotification of transaction
3rd Apr 20071:14 pmRNSLTIP awards
3rd Apr 200711:59 amRNSNotification of transaction
3rd Apr 200711:59 amRNSNotification of transaction
3rd Apr 200711:59 amRNSNotification of transaction
3rd Apr 200711:59 amRNSNotification of transaction
3rd Apr 200710:12 amRNSNotification of transaction
2nd Apr 200712:00 pmRNSNotification of transaction
2nd Apr 200710:27 amRNSNotification of transaction
2nd Apr 200710:26 amRNSNotification of transaction
2nd Apr 200710:26 amRNSVoting rights and capital
23rd Mar 200710:36 amRNSInterest in shares
22nd Mar 20077:03 amRNSFinal Results
26th Jan 200710:49 amRNSCompletion of Acquisition
22nd Jan 20077:02 amRNSHikma enters oncology market

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.